Novotarg

N/A

Report date: 2025/03/20 09:12:05

Base Information

Drug NameNovotarg
Drug Alias NameAPO (Baliopharm)APO
ClassificationBiologics > Protein drugs > Recombinant proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionB-lymphocyte antigen CD20 inhibitorsApoptosis-mediating surface antigen FAS inhibitors
TargetsApoptosis-mediating surface antigen FASB-lymphocyte antigen CD20
Therapy Area/IndicationsInflammationAutoimmune DiseasesHematologic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumGermanySwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEberhard Karls University Tübingen
China Registration ClassN/A

Develop Information

Active CompaniesCellaion SA
Inactive CompaniesBaliopharm AgEberhard Karls University Tübingen
Active IndicationsInflammationAutoimmune DiseasesHematologic Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A